Vilazodone, a novel, dual-acting antidepressant: Current status, future promise and potential for individualized treatment of depression

Personalized Medicine

Volumn 6, Issue 2, 2009, Pages 217-224

  Rickels, Karl ^a   Athanasiou, Maria ^b   Reed, Carol ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PGxHealth LLC   (United States)

Author keywords

5 HT1A agonist; Biomarker; Depression; Pharmacogenomics; Selective serotonin reuptake inhibitor; SSRI; Vilazodone

Indexed keywords

PLACEBO; SEROTONIN 1A RECEPTOR; VILAZODONE;

CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENETIC MARKER; HAPLOTYPE; HUMAN; IC 50; MAJOR DEPRESSION; NAUSEA; NAUSEA AND VOMITING; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SEXUAL DYSFUNCTION; VOMITING;

EID: 67651165427     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.6.2.217     Document Type: Review

References (35)

1. Kessler RC, Chiu WT, Demler O et al.: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62, 617-627 (2005).
2. Ustun TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ: Global burden of depressive disorders in the year 2000. Br. J. Psychiatry 184, 393-403 (2004).
3. Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: acute and continuation treatment of major depressive disorder. World J. Biol. Psychiatry 3, 5-43 (2002).
4. Entsuah AR, Huang H, Thase ME: Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J. Clin. Psychiatry 62, 869-877 (2001).
5. Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC: Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuprake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol. Psychiatry 62, 1217-1227 (2007).
6. Rush AJ: Limitations in efficacy of antidepressant monotherapy. J. Clin. Psychiatry 68 (Suppl. 10), 8-10 (2007).
7. Trivedi MH, Rush AJ, Wisniewski SR et al.; STAR* D Study Team: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163, 28-40 (2006).
8. Mitchell AJ: Two-week delay in onset of action of antidepressants: new evidence. Br. J. Psychiatry 188, 105-106 (2006).
9. Masand PS: Tolerability and adherence issues in antidepressant therapy. Clin. Ther. 25, 2289-2304 (2003).
10. Cramer JA, Rosenheck R: Compliance with medication regimens for mental and physical disorders. Psychiatr. Serv. 49, 196-201 (1998).
11. Nierenberg AA: Predictors of response to antidepressants general principals and clinical implications. Psychiatr. Clin. North Am. 26, 345-352 (2003).
12. Winterer G, Ziller M, Linden M: Classification of observational data with artificial neural networks versus discriminant analysis in pharmacoepidemiological studies - can outcome of fluoxetine treatment be predicted? Pharmacopsychiatry 31, 225-231 (1998).
13. Rosenzweig-Lipson S, Beyer CE, Hughes ZA et al.: Differentiating antidepressants of the future: efficacy and safety. Pharmacol. Ther. 113, 134-153 (2007).
14. Rickels K, Athanasiou M, Robinson DS, Gibertini M, Whalen H, Reed CR: Vilazodone, evidence for efficacy and tolerability in the treatment of major depressive disorder: a randomized, double-blind placebo-controlled trial. J. Clin. Psychiatry (2009) (In press).
15. Rickels K, Athanasiou M, Robinson D, Gibertini M, Whalen H, Reed CR: Vilazodone: evidence for efficacy and tolerability in the treatment of major depressive disorder. Poster presented at: The American Psychiatric Association Annual Meeting. DC, USA, 3-8 May 2008.
16. Bartoszyk GD, Hegenbart R, Ziegler H: EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties. Eur. J. Pharmacol. 322, 147-153 (1997).
17. Heinrich T, Böttcher H, Gericke R et al.:- Synthesis and structure - activity relationship in a class of indolebutylpiperazines as dual 5-HT(1A) receptor agonists and serotonin reuptake inhibitors. J. Med. Chem. 47, 4684-4692 (2004).
18. Heinrich T, Böttcher H, Schiemann K et al.: Dual 5-HT1A agonists and 5-HT re-uptake inhibitors by combination of indole-butylamine and chromenonyl-piperazine structural elements in a single molecular entity. Bioorg. Med. Chem. 12, 4843-4852 (2004).
19. Blier P, Ward NM: Is there a role for 5-HT1A agonists in the treatment of depression? Biol. Psychiatry 53, 193-203 (2003).
20. Bielski RJ, Cunningham L, Horrigan JP et al.: Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel- group study. J. Clin. Psychiatry 68, 571-577 (2008).
21. Gammans RE, Stringfellow JC, Hvizdos AJ et al.: Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. A meta-analysis of eight randomized, controlled studies. Neuropsychobiology 25, 193-201 (1992).
22. Robinson DS, Rickels K, Feighner J et al.: Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J. Clin. Psychopharmacol. 10(3 Suppl.), 67S-76S (1990).
23. Whale R, Terao T, Cowen P, Freemantle N, Geddes J: Pindolol augmentation of serotonin reuptake inhibitors for the treatment ofdepressive disorder: a systematic review. J. Psychopharmacol. (Oxford) (2008) (Epub ahead of print).
24. Hughes ZA, Starr KR, Langmead CJ et al.: Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur. J. Pharmacol. 510, 49-57 (2005).
25. Page ME, Cryan JF, Sullivan A et al.: Behavioral and neurochemical effects of 5-(4-[4-(5-cyano-3-indolyl)-butyl)-butyl]-1- piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist. J. Pharmacol. Exp. Ther. 302, 1220-1227 (2002).
26. Levin GM, Bowles TM, Ehret MJ et al.: Assessment of human serotonin 1A receptor polymorphisms and SSRI responsiveness. Mol. Diagn. Ther. 11, 155-160 (2007).
27. Haenisch B, Linsel K, Brüss M et al.: Association of major depression with rare functional variants in norepinephrine transporter and serotonin(1A) receptor genes. Am. J. Med. Genet. B Neuropsychiatr. Genet. (2008) (Epub ahead ofprint).
28. Wilkie MJ, Smith D, Reid JC et al.: A splice site polymorphism in the G-protein β subunit influences antidepressant efficacy in depression. Pharmacogenet. Genomics 17, 207-215 (2007).
29. Maier W, Zobel A: Contribution of allelic variations to the phenotype of response to antidepressants and antipsychotics. Eur. Arch. Psychiatry Clin. Neurosci. 258(Suppl. 1), 12-20 (2008).
30. Kato M, Serretti A: Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol. Psychiatry (2008) (Epub ahead of print).
31. Arranz MJ, Munro J, Birkett J et al.: Pharmacogenetic prediction of clozapine response. Lancet 355, 1615-1616 (2000).
32. Ioannidis JP, Ntzani EF, Trikalinos TA, Contopoulos-Ioannidis DG: Replication validity of genetic association studies. Nat. Genet. 29, 306-309 (2001).
33. Trikalinos TA, Ntzani EE, Contopoulos- Ioannidis DG, Ioannidis JP: Establishment of genetic associations for complex diseases is independent of early study findings. Eur. J. Hum. Genet. 12, 762-769 (2004).
34. Ioannidis JP, Ntzani EE, Trikalinos TA: Racial differences in genetic effects for complex diseases. Nat. Genet. 36, 1312-1318 (2004).
35. van't Veer LJ, Bernards R: Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452, 564-570 (2008)